Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities

By Frontera News | July 19, 2022

FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may result in blindness. Investors in the $160 million Series B round include Boyu Capital, Sequoia China, and existing investors OrbiMed and Creacion Ventures, who were […]

Read More